← All trials
NCT04314544
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2020
- Primary completion
- Aug 11, 2021
- Completion date
- Aug 10, 2022
- First posted
- Mar 19, 2020
- Last posted
- Apr 6, 2020
- Enrollment
- 472
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.